- Global trial designed to study the safety, tolerability and efficacy of
bemcentinib in combination with current standard of care -

BERGEN, Norway, March 9, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced the first patient was dosed in a
Phase 1b/2a trial evaluating bemcentinib in combination with the current
standard of care, immune checkpoint inhibitor pembrolizumab and doublet
chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer
(NSCLC) patients harboring STK11 mutations (STK11m).

"Approximately 20% of non-squamous NSCLC patients harbor STK11m and do not
currently have effective treatment options," said Martin Olin, Chief Executive
Officer of BerGenBio. "One specific attribute of this group is that they almost
all demonstrate high levels of AXL activation. We are elated to have dosed the
first patient in our trial and to continue our evaluation of bemcentinib and its
ability to inhibit AXL to revive STK11m NSCLC patients' response to checkpoint
inhibitors and chemotherapy."

The trial's lead investigator, Rajwanth Veluswamy, M.D., MSCR, Assistant
Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine
at Mount Sinai (New York, NY), commented, "Today, STK11 mutations are correlated
with a very poor prognosis for patients suffering from NSCLC. These mutations
are widely recognized for their ability to impede the activity of anti-PD-1/L1
therapy. My colleagues and I are driven to find a better outcome for this large
patient population and are eager to assess bemcentinib's potential in achieving
this goal."

The global, open-label Phase 1b/2a trial is designed to determine the safety,
tolerability and efficacy of bemcentinib with standard of care treatments in
untreated advanced/metastatic non-squamous NSCLC patients with STK11 mutations
and no actionable mutations. The Phase 1b portion of the study will evaluate the
safety and feasibility of bemcentinib in combination with pembrolizumab and
doublet chemotherapy in 1L advanced/metastatic non-squamous NSCLC patients,
regardless of STK11 status. The Phase 2a expansion part will assess the efficacy
of bemcentinib in the same treatment combination in 1L advanced/metastatic non
-squamous NSCLC patients with STK11 mutations.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases. The Company is focused on advancing its lead candidate,
bemcentinib, a potentially first-in-class, oral, selective AXL inhibitor in
STK11 mutated NSCLC and severe respiratory infections including COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.